字号·· | 护眼
time

一种新药或可降低二次中风风险A New Pill Could Reduce the Risk of Having a Second Stroke

点「原文对照」整页切到原文,或双击某段只看那段的原文。

——utah778——盖蒂图片社—utah778—Getty Images

2021年11月9日,美国食品药品监督管理局(FDA)批准了一种新型药物,用于降低特定人群的中风风险。

On November 9, the U.S. Food and Drug Administration (FDA) approved a new type of medication to reduce the risk of strokes in certain populations.

阿苏德辛(Asundexian),品牌名为Sunharbo,是一种每日口服的药片,首次针对血液凝固过程中的特定因子,该因子可能导致中风。拜耳向FDA提交的研究显示,药物与阿司匹林等抗血小板治疗联合使用时,在一年多的时间内,相比仅接受安慰剂加抗血小板治疗的患者,可将再次中风的风险降低26%。该药获批用于近期发生缺血性中风(即血块阻塞脑部血流)或短暂性缺血发作(因血流暂时阻塞导致脑部供血中断但未造成永久性损伤)的人群。

Asundexian, which will be sold under the brand name Sunharbo, is a daily pill that is the first to target a specific factor in the blood-clotting process that can contribute to stroke. In a study submitted to the FDA by Bayer, researchers found that the drug, when combined with an antiplatelet therapy such as aspirin, reduced the risk of an additional stroke by 26% in just over a year compared to people who received placebo and the antiplatelet therapy. The drug is approved for people who have recently had an ischemic stroke, which occur when clots block blood flow to the brain, or a transient ischemic attack caused by a temporary blockage of blood flow to the brain that doesn’t cause permanent damage.

“数据相当稳健,国际中风界的反馈也很积极,”共同主持试验的麦克马斯特大学医学教授阿什坎·肖阿曼什(Dr. Ashkan Shoamanesh)说。“我们希望尽快让患者使用这款药物。”

“The data is quite robust, and the feedback from the international stroke community is positive,” says Dr. Ashkan Shoamanesh, professor of medicine at McMaster University, who co-led the trial. “We’re eager to have this on hand as soon as possible for patients.”

中风主要有两种类型:缺血性中风是由于血管阻塞导致血流受阻,影响包括大脑在内的关键器官;出血性中风是因血管脆弱破裂在大脑内出血,导致大量出血。美国约87%的中风为缺血性中风。

There are two types of strokes: ischemic strokes, caused by blockages in the blood vessels, can impede blood flow to critical organs including the brain, and hemorrhagic strokes, caused by weakened blood vessels that burst in the brain and cause excessive bleeding. About 87% of strokes in the U.S. are ischemic.

美国每年约有79.5万人发生中风,其中近四分之一的中风发生在曾经中风过的人身上。肖阿马内什表示,复发性中风是一个尚未得到满足的治疗难题。但治疗缺血性中风需要使用恰到好处的溶栓或抗凝血药物,既能溶解堵塞物,又不会导致过度出血。阿孙德西安似乎正好能做到这一点。根据拜耳的数据,中风风险降低了26%,而出血事件并未显著增加。

Each year, about 795,000 people in the U.S. have a stroke, and nearly one in four strokes occur in people who have previously had one. Recurrent strokes represent an unmet treatment challenge, says Shoamanesh. But treating ischemic strokes requires using just enough clot-breaking—or blood thinning—medications to dissolve the blockage without causing excessive bleeding. Asundexian appears to do just that. The 26% reduction in stroke risk occurred without any significant increase in bleeding events, according to Bayer’s data.

“我们过去总是要在疗效和出血风险之间艰难权衡,”肖阿马内什说。“现在我们获得了主要益处,却没有出血风险,所以大家非常兴奋。”研究人员多年前就已知道,一些天生具有较低中风遗传风险的人,血液中一种参与血液凝固的化合物——凝血因子XIa——水平较低。肖阿马内什说,当身体遭受严重出血性创伤(如受伤)时,这种因子对血栓形成的贡献较小,但在较小的血管破裂中作用更大,而其中一些破裂可能促成中风。

“We used to always have a challenging balancing act,” says Shoamanesh. “Here we have the major benefits without the bleeding risk, so there is a large amount of excitement.”Researchers have known for years that some people born with a genetically driven lower risk of stroke have lower levels of a compound involved in blood clotting, called Factor XIa, in their blood. It's a minor contributor to forming clots when the body experiences a major bleeding trauma like an injury, but it plays a bigger role in smaller vessel ruptures, some of which can contribute to stroke, says Shoamanesh.

拜耳首席医疗官克里斯托夫·克嫩博士表示,科学家花了十多年时间才将这一观察转化为可行的药物。但阿孙德西安能阻止血管中可能形成的小血栓变大,避免其增大到阻塞血流。肖阿马内什说,最令研究人员印象深刻的发现之一是,“无论患者年龄多大、来自世界哪个地区、病史如何,或患的是哪种类型的缺血性中风——所有患者似乎都从该治疗中获得了相似的益处。”

It took more than a decade for scientists to turn that observation into a viable medication, says Dr. Christoph Koenen, chief medical officer at Bayer. But asundexian prevents small clots that may form in the vessels from becoming larger ones that can grow to block blood flow. One of the findings that most impressed the researchers was that "it didn’t matter how old people were, from what part of the world, what their medical history was, or what type of ischemic stroke they had—all of the patients seem to benefit similarly from the treatment,” says Shoamanesh.

鉴于在降低复发性中风风险方面取得了令人鼓舞的结果,Koenen 表示,拜耳正在探索“阿苏德西安是否还有其他益处,可以惠及不同的患者群体。”

Given the encouraging results in reducing the risk of recurrent strokes, Koenen says Bayer is exploring "if there are other benefits of asundexian we can bring to different patient populations.”

阿苏德西安将于 11 月起上市。Shoamanesh 预计,患者若要真正从该药物获益,将不得不终身每日服用。对部分研究参与者再跟踪数年的数据显示,服用该药物者与服用安慰剂者相比,中风风险持续较低。“这意味着该药物在后期时间点仍持续提供优势,”他说。“因此,基于数据,我们预期这将是一种终身用药。我们预期这将成为新的标准治疗方案。”

Asundexian will be available starting in November. Shoamanesh expects that in order to truly benefit from the drug, patients will have to take the daily pills for the rest of their lives. Data that tracked some of the study participants for several more years showed that those on the drug continued to show lower risk of stroke compared to those taking placebo. “That means that the drug continued to provide an advantage even at later time points,” he says. “So we expect this to be a lifelong drug based on the data. And we expect this will be the new standard of care.”

阅读媒体原文 ↗